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Abstract
Background: The prevalence of allergic diseases such as asthma has significantly increased worldwide, making it a
public health concern. There is an urgent need for new anti-inflammatory agents with selective pharmacology and
lower toxicity. Plant extracts have been used for centuries in traditional medicine to alleviate inflammatory diseases.
In this work, we evaluated the anti-allergic activity of Cymbopogon citratus (Cy), a medicinal herb used by folk medicine
to treat asthma.
Methods: We used a murine model of respiratory allergy to the mite Blomia tropicalis (Bt) and evaluated certain
parameters known to be altered in this model. A/J mice were sensitized (100 μg/animal s.c.) and challenged (10 μg/
animal i.n.) with Bt mite extract and treated with 60, 120 or 180 mg/kg of Cy standardized hexane extract.
The parameters evaluated included: cellular infiltrate in bronchoalveolar lavage (BAL); eosinophil peroxidase
activity (EPO); histopathological examination of the lung; serum levels of specific IgE, IgG1 and IgG2a; Th2 cytokine
concentrations in BAL and expression of NF-κB.
Results: Our results showed that oral administration of a Cy hexane extract (especially 180 mg/Kg) reduced the
numbers of leukocytes/eosinophils in BAL; the eosinophil peroxidase activity in BAL; the infiltration of leukocytes in
lung tissue; the production of mucus in the respiratory tract; the level of IL-4 in BAL and the nuclear expression of
NF-κB.
Conclusions: The results presented demonstrate the potential of the Cy hexane extract to modulate allergic asthma;
this extract may be an alternative future approach to treat this pathology.
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Background
The prevalence of allergic diseases such as asthma has
increased significantly over the past few years in devel-
oped and developing countries [1]. Dust mites are the
main sources of airborne allergens, and Blomia tropicalis
is an important sensitizing agent in tropical regions,
contributing to the asthma prevalence in Brazil [2].
Allergic bronchial asthma is a complex syndrome
characterized by airflow obstruction, bronchial hyper-
responsiveness and airway inflammation [3] driven by
T-helper type 2 (Th2) cytokines, including IL-4, IL-5
and IL-13 [4]. These cytokines promote IgE synthesis,
stimulate eosinophil growth and differentiation, and
increase mucus production [5]. Although the critical
roles of Th2 cytokines in the pathogenesis of allergic
asthma have been established, the mechanisms for over-
production of Th2 cytokines in asthmatic responses are
not fully understood [6]. Current guidelines for asthma
treatment recommend first-line anti-inflammatory
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therapy with inhaled and, in the most severe cases,
systemic corticosteroids that are effective at control-
ling allergic airway inflammation in most cases; how-
ever, they also pose a significant risk for adverse
effects, such as general or local immune suppression,
diabetes, and adiposity [7]. New or complementary
anti-inflammatory drugs for asthma therapy are
necessary. Historically, herbal medicine has been very
important in the treatment of asthma. Plant extracts
and their components are known to exhibit biological
activities [8]. Our research group has standardized a
model of allergy using the mite Bt [9], obtaining thera-
peutic results with Cissampelos sympodialis and its alkaloid
warifteine [10], as well as Ocimum gratissimum methanolic
extract and rosmarinic acid [11], in the control of allergic
asthma. Our objective in the present study was to
investigate the immunomodulatory effects of Cymbo-
pogon citratus (Cy) and its possible mechanisms in a
murine model of allergy to Blomia tropicalis. The
species (Poaceae-Gramineae), commonly known as
lemongrass, is a spontaneous perennial grass that is
largely distributed around the world, especially in
tropical and subtropical countries [12]. Our group’s
interest in investigating this plant was because it was
often used as a treatment of asthma and other re-
spiratory allergies by folk medicine in the city of
Salvador, Bahia, Brazil [13]. Extracts of dried Cy
leaves are used in traditional medicine for the treat-
ment of inflammation, digestive disorders, diabetes,
nervous disorders, and fever, as well as other health
problems [14]. No report has been found referring to
the anti-allergic property of this species. However,
there is evidence of an anti-inflammatory property,
especially the ability of the essential oils from Cy to
inhibit iNOS and NF-κB [14]. Understanding the
molecular mechanisms underlying the healing proper-
ties of natural products is crucial to finding com-
pounds that could be useful as templates for new
therapeutic drugs in the treatment of allergic diseases.
Methods
Animals
Male A/J mice (25–30 g) were used throughout the
study. Animals were maintained with free access to food
and water. They were obtained from the animal facilities
of the Fundação Oswaldo Cruz, Bahia, Brazil. Groups of
five animals were used in each experiment. All experi-
mental procedures were approved by the Ethical Com-
mittee for Use of Experimental Animals of the
Faculdade de Odontologia, Universidade Federal da
Bahia, Brazil (protocol number: 02/09), and conducted
according to international standards.
Blomia tropicalis extract
Blomia tropicalis mites were cultivated in a fish food-
containing standardized environment, purified with satu-
rated NaCl and lysed in a blender (51BL30; Waring
Commercial, Torrington, CO, USA) in 0.15 M phosphate-
buffered saline, pH 7.4 (PBS). After several centrifugations
with ether (9000 × g for 10 min) to remove lipids, protein
content was determined by Lowry’s method [15]; the
extract was stored at −20 °C until use. Bt extract was stan-
dardized by determining the Blo t 5 allergen concentration
using a commercial capture ELISA (INDOOR Biotech-
nologies, Charlottesville, VA, USA). All batches of Bt that
were used contained 30–40 ng allergen per μg of protein.
Preparation of hexane extract from Cymbopogon citratus
Leaves of Cymbopogon citratus were obtained from
Cachoeira, Bahia, Brazil and a voucher specimen was
deposited in the herbarium from the Institute of Biology,
Federal University of Bahia (UFBA), ALCB 98522. Prep-
aration of the Cy hexane extract was performed accord-
ing to the technique described by Shetty et al. (2008) in
the research laboratory in the medical field (LAPEMM)
of the UFBA [16]. Briefly, dry plant material was pulver-
ized, and crude extract was prepared by a successive
maceration process using hexane. After filtration, the
extracts were concentrated under vacuum at 40 °C.
HPLC-DAD-ESI-MS and CG-MS
HPLC analysis was performed in a Shimadzu Promin-
ence LC-20AT equipped with a SPD-M20A diode array
detector (Shimadzu Corp. Kyoto, Japan). The samples
were injected into a Rheodyne 7125i injector with a
20 μl loop. The column heater was set at 40 °C. The
chromatographic separation was performed with a Luna
Phenomenex C-18 column (250 mm × 4.6 mm × 5 μm).
The compounds were separated using a mobile phase
consisting of 5 % aqueous formic acid (A) and metha-
nol (B) at a flow rate of 1 mL/min. The separation
gradient was 0–20 min 50–70 % B, 20–40 min 70–90 % B,
40–50 min 90–100 % B, 50–60 min 100 % B. The injec-
tion volume was 20 μL. Chromatograms were recorded at
320 nm. The HPLC-MS was obtained in positive electro-
spray mode using an MS (Esquire 3000 Plus, Bruker
Daltonics, Germany), capillary voltage 4500 V, nebulizer
pressure 26 psi, drying gas 6.0 l/min, and gas
temperature 325 °C.
Gas chromatography coupled with mass spectrometry
was performed using a GC-MS-QP5050 (Shimadzu Corp.
Kyoto, Japan), equipped with BPX5 (5 % phenyl polysil-
phenylene siloxane) a capillary column (30 m × 0.25 mm
i.d.,0.25 μm). For GC-MS detection, an electron ionization
system was used with ionization energy of 70 eV. Helium
was the carrier gas, at a flow rate of 1.7 mL/min. Injector
temperature 240 °C, detector temperature 230 °C,
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temperature program, temperature program: 50 °C
(5 min)-250 °C, 5 °C/min. The identification of the com-
ponents was made through comparison of sbstance mass
spectrum with the database of the GC/MS (Willey229,
NIST107, SHIM1607, NIST21).
The extraction of phenolics compounds from Cymbopo-
gon citratus extract was performed using C18 cartridge.
100 mg of extract was suspended into 1 mL of MeOH and
filtered and filtered to separate the precipitate. The C18
cartridge (SEP-PAK Waters) was sequentially conditioned
with 10 mL of MeOH and 10 mL of acidified water
(pH 2.0 with HCl) without allowing the cartridge to dry.
The filtrate was passed through the cartridge and rinsed
with 10 mL of water and the phenolic compounds were
eluted with 10 mL of HPLC-grade methanol. The eluate
was dried under Nitrogen gas furnished 18.2 mg of phen-
olic fraction. This fraction was dissolved in methanol,
filtered through a 0.45-μm nylon syringe filter (Whatman)
and injected into the HPLC system. The insoluble precipi-
tate in methanol was solubilized with dichloromethane for
GC-MS analysis.
Cytotoxicity assay
The cytotoxicity of Cy was evaluated as described by
Stevignyetal (2002) using the tetrazolium salt MTT (3–
4,5-dimethylthiazol-2-yl)-2,5diphenyltetra-zolium bromide
(Sigma) colorimetric method based on the cleavage of
the reagent by dehydrogenases in viable cells (Mosmann,
1983). Stock solutions of the Cy hexane extract were
prepared at 10 mg/mL in DMSO. The solutions were fur-
ther diluted to final concentrations of 1000–1.95 μg/mL.
Cultures were incubated for 48 h at 37 ° C in an atmos-
phere with 5 % CO2. All experiments were performed at
least in duplicate.
Sensitization and challenge with Bt antigen
The murine model of respiratory allergy was induced as
previously described [17]. Briefly, A/J mice (n = 5) were
initially sensitized by two subcutaneous injections (day 0
and day 7) of Bt (10 μg of protein) adsorbed to 4 mg/mL
Al(OH)3 in saline. 24 hours after the last subcutaneous
injection, animals received three intranasal immunization
boosters/challenges with Bt (10 μg/instillation) every
other day. Two days after the last immunization
booster/challenge, they received a final intranasal
challenge of 10 μg Bt. The negative control group
received saline in both sensitization and challenge
procedures. 24 h after the last challenge, the animals
were euthanized with intraperitoneal injections of
xylazine and ketamine (40 mg/kg/body weight).
Treatment with Cymbopogon citratus
The different groups were treated daily from the 8th to
the 14th day of the experimental protocol, one hour
after intranasal challenges on the 8th, 10th, 12th, and
14th days (Fig. 1). Animals were orally administered 60,
120 or 180 mg/kg of Cy or 3 mg/kg of dexamethasone
(Dex). The groups of animals were named: Control,
non-sensitized and saline-treated mice; Bt, Bt-sensitized
and saline-treated mice; Bt/CcH60, Bt/CcH120 and Bt/
CcH180, Bt-sensitized, Bt-challenged and Cy-treated
mice; Bt/Dex, Bt-sensitized and Dex-treated mice.
Bronchoalveolar lavage (BAL)
The trachea was cannulated, and the lungs were care-
fully washed three times with 0.5 mL PBS containing
1 % bovine serum albumin (BSA). The total number of
leukocytes in the BAL was immediately determined in a
hemocytometer using Trypan blue. Differential cell
counts were obtained using May–Grunwald–Giemsa-
stained cytospin preparations. A differential count of at
least 100 cells was performed in a blind fashion in ac-
cordance with standard morphologic criteria.
Eosinophil peroxidase (EPO) activity
EPO activity in cells obtained from BAL was measured
according to a previously described method [18]. Briefly,
cell suspensions were frozen and thawed three times in
liquid nitrogen. After centrifugation at 4 °C for 10 min
at 1000 x g, cell lysates were placed into 96-well
plates (75 μL/well), followed by the addition of
150 μL of the chromogen and substrate solution
(1.5 mmol/L o-phenylenediamine and 6.6 mmol/L
H2O2 in 0.05 mol/L Tris–HCl, pH 8.0). After 30 min
at room temperature, the reaction was stopped by the
addition of 75 μL of 0.2 mol/L citric acid; the absorb-
ance of the samples was determined at 492 nm using
an ELISA reader.
Levels of IL-4 in bronchoalveolar lavage (BAL)
The concentrations of IL-4 in BAL were quantified by a
standard ELISA as recommended by the manufacturer
(BD Pharmingen, USA).
Measurement of anti-Bt IgE, IgG1 and IgG2a antibody
levels in serum
Anti-Bt antibody levels in serum from the different
experimental groups were determined by indirect
ELISA: 96-well micro titer high-binding plates (Costar,
Cambridge, MA, USA) were coated with Bt (100 μg/
well) overnight at 4 °C and blocked for 1 h with PBS-
T containing 10 % fetal calf serum (FCS, Gibco,
Pisley, UK) at room temperature (RT). After this
incubation period, the serum samples were added,
and the plates were incubated overnight at 4 °C.
Biotin-conjugated IgE, IgG1 or IgG2a anti-mouse (BD
Pharmingen, San Diego, CA, USA) was added to the
wells and incubated for 1 h at RT. A solution of
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avidin-horseradish peroxidase (BD Pharmingen, San
Diego, CA, USA) was then added to each well for
30 min. Finally, a solution containing 3,3′,5,5′-tetra-
methylbenzidine and hydrogen peroxide (BD Phar-
mingen, San Diego, CA, USA) was added and
incubated for 30 min at RT; the reaction was then
stopped with 4 M sulfuric acid. The absorbance of
the sample was determined at 492 nm using an
ELISA reader.
Histopathological analysis
The degree of peribronchiolar and perivascular inflam-
mation was evaluated as described previously [19].
Briefly, lung tissues were fixed by inflation with freshly
prepared 10 % (v/v) paraformaldehyde. The specimens
were dehydrated and embedded in paraffin. Tissue
sections (5 μm) were stained with hematoxylin and
eosin to assess cellular infiltration under optical
microscopy with 400× magnification. The data on
quantification of lung inflammation were acquired
using the software Image-Pro Plus Version 6.1 (Media
Cybernetics, San Diego, CA, USA) using the inflam-
matory area index. Additionally, tissue sections were
stained with periodic acid-Schiff to assess the pres-
ence of mucus. A quantitative digital analysis was
performed as described previously [9].
Detection of NF-κB/p65 in lung tissue by Western blot
Lung tissue (200 mg) from each group of mice was
homogenized with lysis buffer (1000 μl RIPA). The sam-
ples were centrifuged for 30 min at 200 × g and 4 °C,
and the supernatant was collected. Protein concentration
was determined by Lowry’s method [16]; 20 μg protein
from each group was separated by 13 % SDS-PAGE (Bio
Rad, Blot SD – MO – USA, 100 v 1.5 h) and electrotrans-
ferred to a nitrocellulose membrane (Hybound – ECL,
Amersham Biosciences, Bio Rad, Blot SD – MO – USA,
15v 30 min). The membrane was blocked with 3 % BSA
(3 g BSA was dissolved in 100 ml PBS) for 2 h at 37 °C
and incubated with polyclonal rabbit anti-NF-kB (1:100)
overnight at 4 °C. The membrane was washed with TBST
(Tris–HCl pH7.5 5 ml, 20 % Tween-20 1.18 ml, NaCl
4.4 g, 500 ml dd Water) for 2 × 10 min, incubated with
HRP labeled secondary monoclonal antibody (1:1000) for
1.0 h at 37 °C, washed with TBST 2 × 10 min and visual-
ized using an ECL Western blot analysis system (GE
Healthcare).
Detection of NF-κB/p65 in the lung tissue by
immunohistochemistry
Lung sections (4 μm) obtained from paraffin blocks were
placed on glass slides treated with poly-L-lysine (Sigma
Diagnostic). The exposure of antigenic epitopes was
achieved by heating (97 ° C) in citrate buffer pH 6.0 for
30 min. Endogenous blocking was performed with 3 %
hydrogen peroxide in methanol for 15 min and then
block was performed for nonspecific binding with 4 mg/
ml bovine serum albumin (BSA) for 20 min. NF-κB/p65
antibody (Sigma) was added to tissue at a concentration
of 1:80 at 4 ° C for 12 h. After washing with PBST, the
sections were incubated with the secondary antibody,
biotinylated IgG (Sigma 1:1000), for 1 h at room
temperature. Signal amplification was performed using
streptavidin-peroxidase (Pearce 1:1000). After develop-
ment of the slides with DAB 3,3′ diaminobenzidine (DAB,
Dako, Carpinteria, USA), the slides were counter-stained
with hematoxylin and mounted with glass coverslips
containing Canada balsam (Riedel de Haen AG, Hannover,
Germany). The data on quantification of NF-κB expres-
sion were acquired using the software Image-Pro Plus
Version 6.1 (Media Cybernetics, San Diego, CA, USA)
using the expression area index.
Fig. 1 Experimental protocol for induction of respiratory allergy. Experimental protocol for induction of respiratory allergy using aluminum
hydroxide-adsorbed Blomia tropicalis extract (BtE) and assessment of the treatment with Cy hexane extract (60, 120 or 180 mg/kg, orally).
[D1] to [D15], days 1 to 15 of experiments
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Fig. 3 HPLC-DAD (320 nm) chromatogram of phenolic fraction of Cy and UV of representative compounds 1, 4, 7, 8, 13 and 15
Fig. 2 Chromatogram obtained by gas chromatography coupled with mass spectroscopy
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Statistical analysis
One-way analysis of variance (ANOVA) and Tukey’s
post-test (for data with normal distribution) were used
to determine the significance between experimental
groups. Differences with p values ≤ 0.05 were considered
statistically significant. Each experiment was repeated at
least two times.
Results
Standardization hexane extract from Cymbopogon citratus
The chromatogram obtained by gas chromatography
coupled with mass spectrometry is presented in Fig. 2.
The analysis showed the main compounds: 2-hydroxy-
4-methyl2-pentanone (3.89 %), elemol (2.53 %), beta
esdesmol (2.30 %), oplapanone (4.79 %), nerolidol epox-
yacetate (2.78 %), phytol acetate (5.66 %), eicosanoic
acid methyl ester (1.89 %), palmitic acid (8.49 %) and
phytol (1.82). The phenolic composition of Cy extract
was investigated using a HPLC method with diode
array and mass spectrometric detection. 15 compounds
tentative peak assignment partly were assigned as sina-
pic acid derivatives with the exception of substances
four and five which can be derived from ferulic acid.
The compounds derivatives of sinapic acid may be
characterized as sinapate esters. The major fragments
were found at m/z 221, 203 and 147. The fragments to
esters of ferulic acid were observed at m/z 195, 155 and
137. The UV spectra (Figs. 3 and 4) corroborate the
proposal for derivatives of cinnamic acids because the
maximum lambda values observed between 290 and
338 nm nm [20].
Cymbopogon citratus has no significant cytotoxicity in
spleen cells from mice
Our results show that cultures treated with different
concentrations of Cy not had significant differences of
dead cells, when compared to the negative control.





























































Fig. 5 Evaluation of the cytotoxicity of Cymbopogon citratus hexane
extract on cultured splenocytes of mice sensitized with Bt antigen.
Effect of hexane extract of Cymbopogon citratus (CyH) on spleen
cells. Cells were exposed to supplemented RPMI medium (Control)
or supplemented RPMI medium and various concentrations of CyH
(1000 at 1,95 μg/ml) by 48 h at 37 °C in an atmosphere with 5 %
CO2. The MTT assay was performed as described in Materials
and Methods






















Fig. 4 TIC chromatogram of phenolic fraction of Cy from HPLC (+) ESI-MS
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Treatment with Cymbopogon citratus hexane extract
decreases the number of inflammatory cells and
eosinophil peroxidase (EPO) levels in mice sensitized with
Bt antigen
As shown in Fig. 6, an increase in total leukocytes
and eosinophils in BAL of Bt-sensitized animals was
observed when compared to the negative control
group (p < 0.001; Fig. 6a). Among the groups treated
with Cy extract, daily oral administration of 60, 120
or 180 mg/kg resulted in a significant reduction in
the number of inflammatory cells and eosinophils (p <
0.001; Fig. 6B) when compared to Bt-sensitized animals.
Animals sensitized with Bt had higher EPO activity in lung
tissue (p < 0.001; Fig. 6C) compared to the control group.
Mice treated with Cy hexane extract showed a significant
reduction in EPO levels in the BAL at all administered
doses (p < 0.001; Fig. 6c). As expected, the oral adminis-
tration of 3 mg/kg Dex significantly suppressed the
number of eosinophils, total inflammatory cells and
























































































































































Fig. 6 Effect of Cymbopogon citratus on leukocytes and EPO activity in the bronchoalveolar lavage (BAL) of Bt-sensitized and challenged A/J mice.
a Total cells counted in BAL; b eosinophilia in BAL; c eosinophil peroxidase (EPO) activity in BAL. Animals were sensitized and treated with saline
(Control), sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with saline (Bt), sensitized with Blomia tropicalis
(100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with Cy hexane extract (CyH) at 60 mg/kg (Bt/CyH60), 120 mg/kg (Bt/CyH120), 180 mg/kg
(Bt/CyH180) or 3 mg/kg dexamethasone (Bt/Dex). Columns represent the mean values of the results obtained from five animals, and error bars
represent the standard deviation from the means. ### p < 0.001 vs. control; ***p < 0.001 vs. Bt group by ANOVA-Tukey
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Treatment with Cymbopogon citratus hexane extract
decreases the levels of Bt-specific IgE, IgG1 and IgG2a in
the serum of mice sensitized with Bt antigen
Figure 7 presents the levels of anti-IgE, IgG1 and
IgG2a specific for Bt in sensitized and treated ani-
mals. As shown in this figure, mite sensitization
induced high levels of these antibodies when com-
pared to the control group (p < 0.001; Fig. 7a-c).
Treatment with 180 mg/kg of Cy significantly reduced
the level of IgE (p < 0.01; Fig. 7a). The oral adminis-
tration of 3 mg/kg Dex significantly reduced the level
of IgE (p < 0.01; Fig. 7a).
Daily oral administration of 120 mg/kg (p < 0.05;
Fig. 3b) or 180 (p < 0.01; Fig. 7b) reduced the levels of
IgG1 in the serum of Bt-sensitized mice. Treatment with
3 mg/kg Dex decreased levels of IgG1 (p < 0.001; Fig. 7b)
in Bt-immunized and challenged mice. Treatment with
Cy did not significantly reduce IgG2a serum immuno-
globulins levels (Fig. 7c).
Treatment with Cymbopogon citratus hexane extract
decreases IL-4 levels in the BAL of Bt-sensitized mice
Levels of IL-4 in the BAL were higher in Bt-immunized



































































































































Fig. 7 Effect of Cymbopogon citratus on the production of IgE (a), IgG1 (b) and IgG2a (c) in the serum of mice sensitized with Bt antigen. A/J
mice were sensitized and treated with saline (Control), sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated
with saline (Bt), sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with Cymbopogon citratus hexane extract
(CyH) at 60 mg/kg (Bt/CyH60), 120 mg/kg (Bt/CyH120), 180 mg/kg (Bt/CyH180) or 3 mg/kg dexamethasone (Bt/Dex). Columns represent the
mean values of results obtained from five animals, and error bars represent the standard deviation from the means. ### p < 0.001 vs. control;
*p < 0.05; **p < 0.01; ***p < 0.001 vs. Bt group by ANOVA-Tukey
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(p < 0.05; Fig. 8). Treatment with 60, 120 or 180 mg/kg
Cy hexane extract led to significant reductions in the
levels of IL-4 (p < 0.05; Fig. 8). No reduction was ob-
served in dexamethasone- treated animals compared to
mice sensitized with Bt and treated with saline (Fig. 8).
Treatment with Cymbopogon citratus hexane extract
decreases inflammatory cell infiltration in lung tissue of
mice sensitized with Bt antigen
Figure 9b shows a cellular infiltrate that is characteristic
of allergic asthma, including leukocyte infiltration
around the bronchioles and perivascular region. Oral
treatment with 60, 120 and 180 mg/kg Cy reduced in-
flammatory cell infiltration around the bronchioles (p <
0.05, Fig. 9c; p < 0.01, Fig. 9d and p < 0.001, Fig. 9e). As
expected, treatment with 3 mg/kg Dex decreased inflam-
mation in the lung tissue of Bt-immunized and chal-
lenged mice (p < 0.001, Fig. 9f ). The reduction of
inflammation was confirmed by quantification of inflam-
matory area.
Treatment with Cymbopogon citratus hexane extract
decreases mucus production in lungs of Bt-immunized
animals
In our experimental model of allergic asthma induced by
mite Blomia tropicalis, intense mucus production can be
observed in the lung tissue of Bt-sensitized and chal-
lenged animals (p < 0.001, Fig. 10b). In contrast, treat-
ment with 60, 120 and 180 mg/kg hexane extract
reduced mucus production (p < 0.05, Fig. 10c; p < 0.01,
Fig. 10d-e). As expected, treatment with 3 mg/kg Dex
decreased production of mucus in lung tissue of Bt-
immunized and challenged mice (p < 0.001, Fig. 10f ).
The reduction of mucus production was further con-
firmed by quantification analysis as shown in Fig. 10g.
Treatment with Cymbopogon citratus hexane extract
decreases the expression of NF-κB p65 in the lungs of Bt-
immunized animals
Note from Fig. 11 the increased nuclear expression of
NF-κB in Bt-immunized and challenged mice when
compared to the control group. Treatment by oral ad-
ministration of 120 mg/kg hexane extract reduced the
expression of NF-κB/p65 compared to Bt-immunized
and challenged mice. As expected, treatment with 3 mg/
kg dexamethasone decreased the expression of NF-κB/
p65 compared to Bt-immunized and challenged mice.
Fig. 12b shows the nuclear staining of anti-NF-κB p65 in
various cells around the bronchioles (p < 0.001, Fig. 8g).
Treatment (v.o.) with 60, 120, and 180 mg/kg doses of
Cy and dexamethasone 3 mg/Kg (Fig. 12c-e) were able
to inhibit the expression of NF-κB p65 in the lungs of
Bt-immunized and challenged animals (p < 0.01 and p <
0.001, Fig. 12g). The reduction of NF-κB/p65 was further
confirmed by quantification of expression area as shown
in Fig. 12g.
Discussion
Cymbopogon citratus is commonly used in folk medicine
to treat nervous and gastrointestinal disturbances and as
an antispasmodic, analgesic, anti-inflammatory, anti-






































Fig. 8 Effect of Cymbopogon citratus on the cytokine IL-4 in BAL of mice sensitized with Bt antigen. A/J mice were sensitized and treated with
saline (Control), sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with saline (Bt), sensitized with Blomia
tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with Cymbopogon citratus hexane extract (CyH) at 60 mg/kg (Bt/CyH60),
120 mg/kg (Bt/CyH120), 180 mg/kg (Bt/CyH180) or 3 mg/kg dexamethasone (Bt/Dex). Columns represent the mean values of results obtained
from five animals, and error bars represent the standard deviation from the means. ### p < 0.001 vs. control; *p < 0.05; **p < 0.01; ***p < 0.001 vs.
Bt group by ANOVA-Tukey
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extracts from Cy leaves have demonstrated antioxidant,
anti-microbial and anti-fungal activities [22]. The chro-
matogram obtained by gas chromatography coupled
with mass spectrometry showed the main compounds
with different profile for nonpolar substances from Cy
extract may be attributed to the extraction method. Of
the substances identified some have been previously ob-
served in aqueous extract of Cy, such as β-eudesmol,
that has anti-inflammatory activity by suppression of the
NF-kappaB-expression [22, 23]. However, no previous
study has explored the anti-allergic potential of Cy.
We have previously demonstrated the ability of natural
products to modulate inflammatory cell recruitment to
lung tissue [10]. Eosinophilia, eosinophil migration to
the lungs, and their secreted products, such as inflam-
matory cytokines, are important factors that determine
the severity and exacerbation of allergic diseases [18].
The present study was performed using a murine model
of allergic disease induced by a common aeroallergen
described by our group [9]. This work showed that treat-
ment with Cymbopogon citratus reduced the infiltration
of total leukocytes, particularly eosinophils, mucus
production, and NF-κB expression in the lung tissue of
Bt-sensitized animals. Treatment with the extract also
reduced the production of eosinophil peroxidase, and
suppressed levels of IgE, IgG1 and IL-4. Our results
show that Cy suppressed EPO activity at all tested doses
in Bt-sensitized animals. These data are related to the
reduction in the number of eosinophils in the BAL of
animals treated with Cymbopogon citratus, highlighting
the important role of Cy extract in reducing inflamma-
tion and remodeling of lung tissue in allergic asthma.
An emerging concept asserts that the nature and inten-















































Fig. 9 Effect of treatment with Cy on leukocyte infiltration in lung tissue of mice sensitized with Bt antigen. Sections were stained with
hematoxylin-eosin (magnification × 400). Lung section from animal sensitized and treated with saline a, sensitized with Blomia tropicalis (100 μg/animal)
and 4 mg/mL of [AL(OH)3] and treated with saline b, sensitized with Bt (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with Cy hexane extract
(CyH) at 60 mg/kg c, 120 mg/kg d, 180 mg/kg e or 3 mg/kg dexamethasone f. Quantification of lung inflammation g. Scale bar, 100 μm. Each column
represents the mean of inflammatory area index of 5 mice, and the vertical bars represent the standard deviation of the mean. ### p < 0.001 vs. control;
*p < 0.05; **p < 0.01; ***p < 0.001 vs. Bt group by ANOVA-Tukey
Santos Serafim Machado et al. BMC Complementary and Alternative Medicine  (2015) 15:168 Page 10 of 14
particular the presence or absence of increased numbers
of eosinophils, defines disease pathophysiologically and
clinically [24].
The majority of asthma cases are associated with Th2-
type T-lymphocyte–driven cell recruitment and mediator
release involving mast cells, eosinophils, basophils, and
macrophages that contribute to chronic, sub acute, and
acute inflammatory responses [25]. Inflammatory cyto-
kines such as IL-4, IL-5 and IL-13 are induced in the
lung during asthma exacerbations [25]. To evaluate the
mechanism of the Cy-mediated modulation of eosinophil
infiltration, we investigated the effect of Cymbopogon
citratus on the production of the Th2-type cytokine IL-4.
Inhibition of inflammation is an essential process to
establish homeostasis. We observed reduced levels of IL-4
after oral administration of 60 mg/kg, 120 mg/kg and
180 mg/kg Cy extract when compared to Bt-sensitized
and treated with saline animals.
An important, consistent feature of asthma is the pro-
duction of excess, altered mucus that blocks peripheral
airways [25]. In asthma, there is ample evidence for gob-
let cell metaplasia involving the conducting airways; IL-4
and IL-13 also induce the production of TGF-β by epi-
thelial cells that, through autocrine signaling, results in
the mucus metaplasia that is characteristic of Th2-
mediated inflammation [24]. Animals treated with the
Cy hexane extract showed reduced mucus production in
lung tissue, at all doses administered, stained with PAS.
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Fig. 10 Effect of treatment with Cy on mucus production in lung tissue of mice sensitized with Bt antigen. Sections were stained with periodic
acid-Schiff (magnification × 400). Sections were stained with hematoxylin-eosin (magnification × 400). Lung sections from animals sensitized and
treated with saline a, sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with saline b, sensitized with Blomia
tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with Cymbopogon citratus hexane extract (CyH) at 60 mg/kg c, 120 mg/kg d,
180 mg/kg e or 3 mg/kg dexamethasone f. Scale bar, 100 μm. Each column represents the mean of the mucus indexes of 5 mice, and the vertical
bars represent the standard deviation of the mean. ### p < 0.001 vs. control; *p < 0.05; **p < 0.01; ***p < 0.001 vs. Bt group by ANOVA-Tukey
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These results suggest decreased hyperplasia and hyper-
secretion of goblet cells in the airways obstruction a
common feature in asthma pathology.
Our results showed that treatment with 180 mg/kg
Cy extract decreased the levels of Bt-specific IgE in
Bt-immunized mice; the levels of IgG1 were decreased
when mice were treated with 120, 180 mg/kg Cy
extract. Production of IgE depends on Th2-type cyto-
kines, such as IL-4 [26]. Down-modulation of IgE
production, as well as the reduction of IL-4, constitutes an
important strategy for treating allergic diseases be-
cause the treatment of allergic asthma patients with
IgE antibody was confirmed to attenuate eosinophilic
airway inflammation [27] may have an important
anti-allergic effect.
A B C 
















































Fig. 12 Effect of Cymbopogon citratus treatment on expression of NF-κB p65 in the lung tissue of mice sensitized with Bt antigen. Sections were
stained by immunohistochemistry (magnification × 400). Lung sections from A/J mice sensitized and treated with saline a, sensitized with Blomia
tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated with saline b, sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of
[AL(OH)3] and treated with Cymbopogon citratus hexane extract (CyH) at 60 mg/kg c, 120 mg/kg d, 180 mg/kg e or 3 mg/kg dexamethasone f. g




Fig. 11 Detection of NF-κB expression in lung tissue of mice sensitized
with Bt antigen. A/J mice were sensitized and treated with saline
(Control), sensitized with Blomia tropicalis (100 μg/animal) and
4 mg/mL of [AL(OH)3] and treated with saline (Bt) or sensitized with
Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)3] and treated
with Cymbopogon citratus (Cy) hexane extract at 120 mg/kg (Bt/CyH120)
or 3 mg/kg dexamethasone (Bt/Dex). Each lane is representative of the
results obtained from five animals
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The molecular mechanisms underlying the protective
effects of Cy in allergic asthma are not fully established.
However, Edwards and colleagues (2009) found that the
anti-inflammatory effects of Cy may be due to suppression
of NF-κB activation [28]. One of the molecular mecha-
nisms related to the effect of glucocorticoids is the inhib-
ition of transcription factors such as NF-κB that are
related to the production of inflammatory cytokines [29].
NF-κB exists in the cytoplasm in a latent form as a
complex consisting of a dimer of DNA-binding subunits
bound to an inhibitor, IκB. Activating agents, such as
cytokines or lipopolysaccharide (LPS), induce the deg-
radation of cytosolic IκB, promoting the release and
nuclear translocation of NF-κB dimers. In most cells, the
NF-κB is a heterodimer composed of the p65 and p50
subunits. This variant is the most potent gene transacti-
vator among the NF-κB family and is the major NF-κB
protein found in the nucleus of cytokine-stimulated
cells. The transcription factor NF-κB is a central regula-
tor of the transcriptional activation of a number of genes
involved in proinflammatory responses [30].
Lee and colleagues (2008) found that Citral, a of the
major compound of Cy inhibited iNOS expression, NO
production and various LPS-induced pathways, includ-
ing p38 mitogen-activated protein kinase (MAPK), c-jun
NH2-terminal kinase (JNK) 1/2 and the transcription
factor NF-kB [14]. In this work, we showed that treat-
ment with our Cy extract at all administered doses
reduced NF-κB/p65 expression in the lung tissue of Bt-
sensitized animals, as determined by immunohistochem-
istry (Fig. 12). We also showed that treatment with
Cymbopogon citratus at a dose of 120 mg/kg decreased
NF-kB nuclear expression in lung tissue when compared
to control groups of Bt-sensitized mice or mice sensi-
tized with saline (Fig. 11). This may be one of the prob-
able mechanisms mediating the anti-allergic effect of Cy.
These findings are consistent with and corroborated by
Francisco and collaborators (2011) which evidences the
potential of Cy as source of compounds with anti-
inflammatory properties, as well as the expression of
NF-κB [21]. The data suggest that Cymbopogon citratus
is a potential herb that can be used to control allergic
asthma, reducing extensive infiltration of inflammatory
cells into the lungs while also potentially inhibiting NF-
κB expression in the lung. Further studies are needed to
verify the exact mechanism of action of the Cymbopogon
citratus extract, to identify the possible active com-
pounds within the extract responsible for the properties
observed and the mechanism whereby it occurs.
Conclusion
The results presented in this study demonstrate the anti-
allergic activity of Cymbopogon citratus extract in an
experimental murine model of allergic asthma. Add-
itional studies are being conducted in our group to de-
scribe possible mechanisms involved in allergic disease
control by using Cy, as well as, isolated Cy compounds.
Abbreviations
BAL: Bronchoalveolar lavage; BSA: Bovine serum albumin; Bt: Blomia tropicalis;
ECL: Enhanced chemiluminescence; ELISA: Enzyme immunoassay test;
EPO: Eosinophil peroxidase; HBSS: Hanks’ balanced salt solution;
HCl: Hydrochloric acid; IL: Interleukin; IL-4: Interleukin 4; IL-5: Interleukin 5;
IL-13: Interleukin 13; IFN-γ: Interferon gamma; i.n.: Intranasal;
IgE: Immunoglobulin E-type; LPS: Lipopolysaccharide NaCl Sodium chloride;
NaOH: Sodium hydroxide; NF-κB: Nuclear factor-κB; OVA: Ovalbumin;
OD: Optical density; PAS: Periodic acid schiff; PBS: Phosphate-buffered saline;
PBST: Phosphate-buffered saline containing 0.05 % Tween; PWM: Pokeweed
mitogen; RPM: Revolutions per minute; s.c.: Subcutaneous; Th1: T helper
lymphocyte type 2; Th2: T helper lymphocyte type 2; Treg: Regulatory T
lymphocytes; v.o.: Oral; RIPA: Lysis buffer system; iNOS: Inducible nitric oxide
synthase.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MMSS significantly contributed to performed the present study, wrote the
manuscript and conducted the laboratory assays. SHB, RR, AO and CRS
helped in the study design, conducted the laboratory assays and manuscript
revision. QNV and WAS helped the laboratory assays. FLM and VES
contributed to the collection of Cy and production of extract. SSA and STMS
contributed technical chromatographic and spectrometry. PCLC and ANNM
contributed technical support for the development of this work. FCA
conceived the work, the study design, supervised the immunological assays
and manuscript revision. TMSS and SAS contributed to the standardization of
the Cy extract. All authors read and approved the final manuscript.
Acknowledgments
The authors wish to thank the Brazilian agencies FAPESB, FACEPE, CNPq and
CAPES for financial support.
Author details
1Departamento de Biorregulação, Instituto de Ciências da Saúde,
Universidade Federal da Bahia, Campus do Canela, CEP 41110-100 Salvador,
BA, Brazil. 2Centro de pesquisa Gonçalo Moniz, Fundação Oswaldo Cruz,
Salvador, Bahia, Brazil. 3Faculdade Adventista da Bahia, Cachoeira, Bahia,
Brazil. 4Faculdade de Farmácia da Universidade Federal da Bahia, Salvador,
Bahia, Brazil. 5Departamento de Ciências Moleculares, Laboratório de
Bioprospecção Fitoquímica da Universidade Federal Rural de Pernambuco,
52171-900 Recife, Pernambuco, Brazil. 6Instituto de Biologia, Universidade
Federal da Bahia, Salvador, Bahia, Brazil.
Received: 8 February 2014 Accepted: 29 May 2015
References
1. Bousquet J, Dahl R, Khaltaev N. Global alliance against chronic respiratory
diseases. Eur Respir J. 2007;29:233–9.
2. Sade K, Roitman D, Kivity S. Sensitization to dermatophagoides, blomia
tropicalis, and other mites in atopic patients. J Asthma. 2010;47:849–52.
3. Medeiros KC, Figueiredo CA, Figueredo TB, Freire KR, Santos FA, Alcantara-
Neves NM, et al. Anti-allergic effect of bee pollen phenolic extract and
myricetin in ovalbumin-sensitized mice. J Ethnopharmacol. 2008;119:41–6.
4. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic
evaluation of severe asthma. Persistent inflammation associated with high
dose glucocorticoids. Am J Respir Crit Care Med. 1997;156:737–43.
5. Castro M, Chaplin DD, Walter MJ, Holtzman MJ. Could asthma be worsened
by stimulating the T-helper type 1 immune response? Am J Respir Cell Mol
Biol. 2000;22:143–6.
6. Hogan SP, Mould A, Kikutani H, Ramsay AJ, Foster PS. Aeroallergen-induced
eosinophilic inflammation, lung damage, and airways hyperreactivity in mice
Santos Serafim Machado et al. BMC Complementary and Alternative Medicine  (2015) 15:168 Page 13 of 14
can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin
Invest. 1997;99:1329–39.
7. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M, et al.
Global strategy for asthma management and prevention: GINA executive
summary. Eur Respir J. 2008;31:143–78.
8. Işcan G, Kirimer N, Kürkcüoğlu M, Başer KH, Demirci F. Antimicrobial
screening of Mentha piperita essential oils. J Agric Food Chem.
2002;50:3943–6.
9. Baqueiro T, Russo M, Silva VM, Meirelles T, Oliveira PR, Gomes E, et al.
Respiratory allergy to Blomia tropicalis: immune response in four
syngeneic mouse strains and assessment of a low allergen-dose,
short-term experimental model. Respir Res. 2010;11:51.
10. Cerqueira-Lima AT, Alcântara-Neves NM, de Carvalho LC, Costa RS,
Barbosa-Filho JM, Piuvezam M, et al. Effects of Cissampelos
sympodialis Eichl. and its alkaloid, warifteine, in an experimental
model of respiratory
allergy to Blomia tropicalis. Curr Drug Targets. 2010;11:1458–67.
11. Costa RS, Carneiro TC, Cerqueira-Lima AT, Queiroz NV, Alcântara-
Neves NM, Pontes-de-Carvalho LC, et al. Ocimum gratissimum Linn.
and rosmarinic acid, attenuate eosinophilic airway inflammation
in an experimental model of respiratory allergy to Blomia tropicalis.
Int Immunopharmacol. 2012;13:126–34.
12. Negrelle RRB, Gomes EC. Cymbopogon citratus (DC.) Stapf: chemical
composition and biological activities. vol. 9. pp. 80–92, Revista Brasileira
de Plantas Medicinais. 2007. p. 80–92.
13. Costa R, Brasil T, Santos C, Santos D, Barreto M, Alcantara-Neves N,
et al. Avaliação do uso de remédios caseiros para tratamento de
asma em crianças residentes no município de Salvador-BA-Brasil.,
vol. 20. pp. 594–599. Curitiba: Revista Brasileira de Farmacognosia;
2010. p. 594–9.
14. Lee HJ, Jeong HS, Kim DJ, Noh YH, Yuk DY, Hong JT. Inhibitory effect of
citral on NO production by suppression of iNOS expression and NF-kappa B
activation in RAW264.7 cells. Arch Pharm Res. 2008;31:342–9.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with
the Folin phenol reagent. J Biol Chem. 1951;193:265–75.
16. Shetty S, Udupa S, Udupa L. Evaluation of antioxidant and wound healing
effects of alcoholic and aqueous extract of Ocimum sanctum Linn in rats.
Evid Based Complement Alternat Med. 2008;5:95–101.
17. Elias JA, Kang MJ, Crothers K, Crouthers K, Homer R, Lee CG. State of
the art. Mechanistic heterogeneity in chronic obstructive pulmonary
disease: insights from transgenic mice. Proc Am Thorac Soc.
2006;3:494–8.
18. Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M. Eosinophil cationic protein
levels in induced sputum correlate with the severity of bronchial asthma.
Chest. 1997;112:1241–7.
19. Takano H, Osakabe N, Sanbongi C, Yanagisawa R, Inoue K, Yasuda A,
et al. Extract of Perilla frutescens enriched for rosmarinic acid, a
polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis
in humans. Exp Biol Med (Maywood). 2004;229:247–54.
20. Engels C, Schieber A, Gänzle M. Sinapic acid derivatives in defatted
Oriental mustard (Brassica juncea L.) seed meal extracts using
UHPLC-DAD-ESI-MSn and identiFIcation of compounds with
antibacterial activity, pp. 535–542. 2012. p. 535–42.
21. Francisco V, Figueirinha A, Neves BM, García-Rodríguez C, Lopes MC,
Cruz MT, et al. Cymbopogon citratus as source of new and safe
anti-inflammatory drugs: bio-guided assay using lipopolysaccharide-
stimulated macrophages. J Ethnopharmacol. 2011;133:818–27.
22. Halabi MF, Sheikh BY. Anti-proliferative effect and phytochemical analysis of
Cymbopogon citratus extract. Biomed Res Int. 2014;2014:906239.
23. Seo MJ, Kim SJ, Kang TH, Rim HK, Jeong HJ, Um JY, et al. The
regulatory mechanism of β-eudesmol is through the suppression of
caspase-1 activation in mast cell-mediated inflammatory response.
Immunopharmacol Immunotoxicol. 2011;33:178–85.
24. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, et al.
Elevated expression of messenger ribonucleic acid encoding IL-13 in
the bronchial mucosa of atopic and nonatopic subjects with asthma.
J Allergy Clin Immunol. 1997;99:657–65.
25. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation.
Nature. 2008;454:445–54.
26. Corry DB, Kheradmand F. Induction and regulation of the IgE response.
Nature. 1999;402:B18–23.
27. Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on
markers of inflammation in patients with allergic asthma. Allergy.
2009;64:1728–36.
28. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL.
Targeting the NF-kappaB pathway in asthma and chronic obstructive
pulmonary disease. Pharmacol Ther. 2009;121:1–13.
29. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases.
Lancet. 2009;373:1905–17.
30. Ruben SM, Narayanan R, Klement JF, Chen CH, Rosen CA. Functional
characterization of the NF-kappa B p65 transcriptional activator and
an alternatively spliced derivative. Mol Cell Biol. 1992;12:444–54.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Santos Serafim Machado et al. BMC Complementary and Alternative Medicine  (2015) 15:168 Page 14 of 14
